ZAC encodes a zinc ®nger protein with antiproliferative activity, is maternally imprinted and is a candidate for the tumor suppressor gene on 6q24. ZAC expression is frequently lost in breast and ovary tumor-derived cell lines and down-regulated in breast primary tumors. In this report, we describe ZACD2, an alternatively spliced variant of ZAC lacking the sequence encoding the two N-terminal zinc ®ngers. Messenger RNAs encoding ZAC or ZACD2 were equally abundant and both proteins were nuclear. ZACD2 displayed an improved transactivation activity and an enhanced anity for a ZAC binding site, suggesting that the two N-terminal zinc ®ngers negatively regulated ZAC binding to its target DNA sequences. Both proteins were equally ecient in preventing colony formation, indicating similar overall antiproliferative activities. However, these activities resulted from a dierential regulation of apoptosis vs cell cycle progression since ZACD2 was more ecient at induction of cell cycle arrest than ZAC, whereas it was the reverse for apoptosis induction. Hence, these data further underline that ZAC gene is critically controlled, both at the transcriptional level through imprinting and at the functional level through alternative splicing.
Introduction
Transcription factors play a critical role in the complex interplay between signals inducing cell division and cell survival and those designed to control negative feedback loops and eventually cell death. In this context, we previously reported the cloning and functional characterization of cDNAs encoding Zac1, a novel mouse seven-Zinc ®nger protein which displayed an antiproliferative activity by inducing Apoptosis and cell Cycle arrest upon expression in osteosarcoma and kidney epithelial cell lines (Spengler et al., 1997) . Lot1, the rat ortholog of Zac1, was independently cloned by Abdollahi et al. (1997a) from rat ovarian surface epithelial (ROSE) cells which spontaneously transform in vitro. Using dierential display PCR, they isolated a cDNA whose expression is lost in transformed cells compared to their normal counterpart, hence the name Lot1 for`Lost on transformation'. The functional properties of Zac1/Lot1 combined with its loss of expression in an in vitro model of cellular transformation suggested that this gene may be a novel tumor suppressor gene (TSG). Interestingly, Abdollahi and co-workers recently reported a down-regulation of Lot1 mRNA in ROSE cells following addition of EGF receptor ligands, EGF or TGF-a (Abdollahi et al., 1999) . Zac1/Lot1 may therefore be involved in a feedback loop, aimed at control of cell proliferation and negatively modulated by potent mitogens. Moreover, the recent demonstration that Zac1 interacts with members of the steroid receptor superfamily and their associated co-activators suggests that Zac1 may play a general role in controlling the proliferation of hormone-dependent tissues (Huang and Stallcup, 2000) .
The human ortholog ZAC/LOT maps on chromosome 6q24 ± q25 (Abdollahi et al., 1997b; Varrault et al., 1998) , a region known to harbor a TSG for several types of neoplasms including breast cancer (Chappell et al., 1997; Devilee et al., 1991; Fuji et al., 1996; Negrini et al., 1994; Nishizaki et al., 1997; Noviello et al., 1996; Orphanos et al., 1995; Sheng et al., 1996; Theile et al., 1996) . We con®rmed that ZAC displays functional properties similar to those of its mouse ortholog and is a bona ®de transcription factor displaying DNA binding and transactivation activities (Varrault et al., 1998) . More recently, we showed that ZAC is expressed in normal mammary epithelial cells and that its expression is lost in mammary tumor-derived cell lines and downregulated in primary breast tumors (Bilanges et al., 1999) . Interestingly, treatment of some mammary cell lines with 2-deoxy-azacytidine led to ZAC reexpression, indicating that ZAC may be inactivated by promoter methylation (Bilanges et al., 1999) . The recent demonstration that ZAC is imprinted in humans (cf. infra) further strengthens our suggestion that ZAC promoter methylation status is critical in controlling its expression and suggests an additional mechanism for inactivation of ZAC in tumors with loss of heterozygosity (LOH) at 6q24 ± q25, a condition observed in up to 80% of breast tumors (Fuji et al., 1996) .
Recent studies (Gardner et al., 2000; Kamiya et al., 2000) suggest an additional role for ZAC in the aetiology of transient neonatal diabetes mellitus (TNDM). This form of neonatal diabetes is of genetic origin and results from the overexpression of a maternally imprinted gene localized on 6q24 ± q25 which interferes with the development and/or the maturation of pancreatic b-cells (Ferguson and Milner, 1970) . The report by Kamiya et al. (2000) demonstrates that ZAC is maternally imprinted in human tissues and localizes to the 400 kb-minimal chromosomal interval shown to harbor the gene responsible for TNDM (CaveÂ et al., 2000; Gardner et al., 2000) . Hence its antiproliferative properties, imprinting status and chromosomal localization make ZAC a strong candidate for TNDM.
Alignment of the previously characterized ZAC cDNA (Varrault et al., 1998) with dierent ESTs indicated the possible existence of an alternatively spliced variant of ZAC. The present report describes the functional characterization of this variant, which we named ZACD2 because it displays a deletion of the exon encoding the two N-terminal ZFs of the previously reported ZAC protein.
Results

Identification of ZAC alternative splice variants
We previously reported the isolation of a human pituitary cDNA encoding ZAC (Varrault et al., 1998) . To elucidate the organization of ZAC gene, we screened a human BAC genomic library (release I, GenomeSystems, Inc.) and isolated a clone (No. 64O1) comprising all sequences present in the pituitary cDNA clone within a 70 kb insert. Partial sequencing of this clone was in agreement with the sequence of the 300 kb-contig (NT_007174) released by the Sanger Centre during the course of this study and allowed the localization of some of ZAC exons (Figure 1a) . Exon-intron boundaries were in agreement with donor and acceptor consensus sites (Figure 1b) .
Using a ZAC cDNA full-length probe, Northern blot analysis of human mammary and pituitary glands previously revealed several ZAC transcripts ranging in size from 3 ± 8 kb (Bilanges et al., 1999) , suggesting the presence of alternatively spliced mRNAs and/or the use of alternative promoters and/or polyadenylation sites. BLAST searches of dbEST revealed numerous expressed sequence tags (ESTs) matching ZAC sequence. While most ESTs matched ZAC 3' UTR, ®ve were found to match more 5' sequences of ZAC last exon, which we numbered`n' because the number of exons making up ZAC 5' UTR has not been determined so far. Four ESTs (AL041267, AA778209, W80612, AU136661) had a similar organization and contained exons n-2 and n but not exon n-1 (see Figure 1a for numbering of ZAC exons). A fourth EST (AW606609) extended from exon n-1 to n. Together with the pituitary cDNA we previously described which comprised exons n-2, n-1 and n, these ESTs suggested alternative splicing of exon n-1 and we investigated the existence of possible ZAC isoforms using RT ± PCR with primers located in exons n-2 and n ( Figure 1c ) and sequencing (data not shown). Analysis of pituitary gland, placenta, mammary gland, ovary, adrenal gland and fetal liver con®rmed the presence of two types of transcripts with or without exon n-1. The new variant devoid of exon n-1 was named ZACD2 for reasons which will become clear in the following paragraphs. Using the same primer pairs with dierent input of plasmids encoding ZAC and ZACD2, we veri®ed that both isoforms were ampli®ed with the same eciency ( Figure 1c ; right panel) and concluded that ZACD2 Figure 1 Identi®cation of an alternatively spliced variant of ZAC. (a) Genomic organization of ZAC 3'UTR, coding region and proximal 5'UTR. ZAC exons were numbered from the last one (exon n). The coding region (black boxes) was entirely comprised in two exons. ZF1 and most of ZF2 were encoded by exon n-1 whereas ZF3-7 were encoded by the last exon. (b) Sequences of exon-intron boundaries for exons n, n-1 and n-2 (c) RT ± PCR on RNA prepared from various human tissues. 2.5 ng polyA + RNA (pituitary gland) and 100 ng total RNA (placenta and mammary gland, ovary, kidney, adrenal gland and fetal liver) were reverse transcribed and ampli®ed by PCR with primers located in exons n-2 and n. Numbers denote RNA samples prepared from dierent individuals. Equal volume of each RT ± PCR reaction was electrophoresed through a 1% agarose gel, blotted and probed with a probe recognizing both ZAC variants. Primers speci®c for b-actin were used to control for equal RNA input. Linear ampli®cation of both variants was veri®ed by varying the ratio of plasmids comprising ZAC and ZACD2 (right panel) variant was at least as abundant as ZAC in all samples tested, with some noticeable individual variations for placenta and mammary gland. We also investigated ZACD2 vs ZAC downregulation in those breast cancer cell lines displaying detectable ZAC expression (Bilanges et al., 1999) (CAL-51, MDA-MB-157, MCF-7) using RNase protection assay. Both isoforms were present in comparable amount in these cell lines, indicating no preferential downregulation of one splice variant over the other (data not shown).
ZACD2 transcript was translated into a nuclear 44 kDa protein
Splicing of exon n-1 results in the deletion of the previously characterized translation initiation site, raising questions about translation initiation in the novel splice variant. The 5' sequence present in ZACD2 did not display a new in-frame ATG codon and no alternative open reading frame of acceptable size was noted in this variant. On the other hand, the two ®rst in-frame ATG of ZACD2, corresponding to ATG3 and ATG4 of ZAC, did not match the Kozak consensus sequence. To test which translation start site was used in ZACD2, we analysed by Western blot the translation products from cells transfected with expression plasmids encoding ZAC and ZACD2 as well as three cDNA constructs in which ATG1-3 (ZACM4), ATG1-4 (ZACM5) and ATG1-5 (ZACM6) were deleted ( Figure 2a ). As shown in Figure 2b , a polyclonal antiserum raised against a GST ± ZAC(226 ± 463) fusion protein indicated that the main translation product from ZACD2 had a molecular weight larger than the one obtained with ZACM4, indicating initiation at the ®rst in frame ATG in ZACD2 (ATG3 of ZAC) and resulting in deletion of the two ®rst ZFs. ZACM6 was not expressed at a detectable level in these experiments. These results were further corroborated by co-electrophoresis of lysates from transfected cells with in vitro translated proteins (data not shown). The anti-ZAC antiserum used in this experiment was not sensitive enough to detect endogenous ZAC or ZACD2 proteins in any of the tissues tested so far (data not shown).
Additionally, we previously reported (Varrault et al., 1998) that ZAC is localized in the nucleus. In the present study, we demonstrated a strong nuclear labeling of ZACD2-transfected LLC-PK1 cells indicating that the absence of ZF1-2 did not alter ZAC subcellular localization (Figure 2c ). No immunoreactivity was detected in CAT-transfected cells or using preimmune serum (data not shown).
ZACD2 displayed improved DNA binding and transcriptional regulatory activities
Since zinc ®ngers commonly serve DNA binding, we asked whether deletion of ZF1-2 altered the DNA binding activity of ZAC gene products. We previously showed ZAC binding to a GC-rich consensus sequence which was selected in vitro through the SELEX procedure (Varrault et al., 1998) . ZAC and ZACD2 cDNAs were transfected in LLC-PK1 cells and nuclear extracts were prepared and subsequently tested in electrophoretic mobility shift assays (EMSA). Both proteins bound to the same G 4 C 4 consensus oligonucleotide (Figure 3a) . The addition of anti-ZAC antiserum completely abolished the DNA-protein complex formation observed in the absence of serum or in the presence of preimmune serum thus attesting the speci®city of the observed shifts. Interestingly, the ZACD2-speci®c shift exhibited a stronger signal compared to the one obtained with ZAC, despite lower expression of ZACD2 in the depicted experiment. We evaluated the DNA binding anity of each protein by measuring the band intensity obtained with increasing amount of radioactive consensus oligonucleotide probe. Results depicted in Figure 3b indicated that ZAC full-length protein exhibited a lower binding anity than ZACD2. Conclusively, deletion of ZF1-2 enhanced the anity of ZACD2 for a G 4 C 4 consensus binding site indicating that the ®rst two ZFs of ZAC are not involved in direct binding to this motif, but rather negatively modulated ZAC binding to its target DNA sequences.
These ®ndings led us to ask whether the increased DNA binding anity in cell-free systems correlated with improved transactivation in cells in culture. To test this hypothesis, we used a ZAC-responsive reporter construct harboring multiple copies of an oligonucleotide comprising the G 4 C 4 sequence cloned upstream of a TATA element driving the expression of the luciferase cDNA. In line with the data obtained in the EMSA experiments, we showed that ZACD2 transactivated more eciently this reporter construct compared to ZAC (Figure 4 ).
ZACD2 displayed antiproliferative activity
Since dierential ZAC DNA binding correlated well with increased transactivation, we asked further whether these dierences between ZAC and ZACD2 were relevant to their biological activities. We ®rst assessed the overall antiproliferative activity of each variant by performing a colony formation assay and con®rmed that ZAC expression prevents colony formation as previously described (Varrault et al., 1998) . In addition, ZAC and ZACD2 were similarly ecient in reducing the number of puromycin-resistant colonies ( Figure 5 ) indicating no apparent consequence of alternative splicing at this stage.
ZACD2 induced a prominent G1 arrest
The antiproliferative activity of ZAC is due to the concomitant induction of apoptosis and cell cycle arrest (Spengler et al., 1997; Varrault et al., 1998) . We therefore asked whether ZACD2 maintained similar functional properties. First, to investigate the role of ZACD2 on cell cycle progression, we analysed cell cycle distribution of transfected LLC-PK1 cells. As described previously (Spengler et al., 1997; Varrault et al., 1998) ZAC expression induced an increased percentage of cells in G1 phase (30% in control samples vs 48% in ZAC-transfected cells) and a corresponding decrease in the percentage of cells in S and G2/M phases (Table 1) . In this experiment, TP53 was used as a standard gene since it also controls cell cycle progression and induces apoptosis. Unexpectedly, ZACD2 expression induced an enhancement of G1 arrest with 68% of cells in G1 phase. The dierence in the percentage of cells in G0/ G1 following ZAC vs ZACD2 expression were signi®cantly dierent using two-tailed Student's t-test (P50.01; n=5). Western blot performed with the anti-ZAC antiserum demonstrated that the G1 arrest induced by ZACD2 was not due to higher expression of this variant compared to ZAC (data not shown).
Expression of ZACD2 induced apoptosis
We then investigated the eect of ZACD2 expression on induction of apoptosis in LLC-PK1 cells. Cells were co-transfected with a plasmid encoding a C-terminally truncated, inactive mutant of rat CD2, an immunoglobin receptor expressed in some lymphocytes, as a transfection marker. Dead (apoptotic+necrotic) cells were stained with Annexin-V whereas necrotic cells only were stained with 7-amino-actinomycin D. Fortyeight hours after transfection, p53 expression robustly induced apoptosis while ZAC induced apoptosis at a lower extent though a direct comparison is dicult because protein levels cannot be compared. ZACD2 was signi®cantly less ecient than ZAC (Figure 6 ; P=0.025 with Student's t-test; n=4). Expression level of ZAC and ZACD2 were veri®ed by Western blotting in each experiment (data not shown).
Discussion
Due to its functional properties, namely induction of cell cycle arrest and apoptosis, and its chromosomal Figure 5 Expression of ZACD2 prevented colony formation. LLC-PK1 cells were transfected with a plasmid encoding chloramphenicol acetyl transferase (CAT), or co-transfected with plasmids containing the puromycin-resistance gene (PUR) and either CAT, ZAC cloned in the anti-sense orientation (ZACas), ZAC or ZACD2. Data are the mean+s.e.mean of three independent experiments performed in triplicate. Colony number of control condition (CAT+PUR) was 665+93 localization, we previously suggested that ZAC is a novel tumor suppressor gene for breast cancer (Bilanges et al., 1999; Varrault et al., 1998) . We showed that ZAC is not inactivated in breast tumors according to the`two-hit' model proposed by Knudson (1971 Knudson ( , 1993 but, instead, found a frequent loss of expression or down-regulation in breast tumor cell lines and primary samples, through a mechanism involving gene methylation (Bilanges et al., 1999) . In this previous study, Northern blots displayed several mRNA species ranging in size from 3 kb to 7 ± 8 kb suggesting the existence of splice variants, alternative promoters and/or alternative polyadenylation sites. Alignments of the previously cloned cDNAs with the numerous ESTs present in dbEST indicated that the exon comprising the translation initiation site, the ®rst ZF and most of the second one is potentially alternatively spliced (Figure 1a) . Experimental evidence supporting the existence of this novel splice variant was obtained in all tissues expressing ZAC (Figure 1c ). Since alternative splicing of numerous genes was found to be quantitatively anecdotal, we evaluated the relative level of expression of both variants and found that ZACD2 accounts for at least 50% of all ZAC transcripts in all samples examined (Figure 1c and data not shown). Noteworthingly, the ratio of ZAC mRNA to ZACD2 mRNA apparently varies among individuals, at least in the placenta and mammary gland (Figure 1c) . Further studies will be necessary to determine whether this heterogeneity is due to polymorphic variations among human populations or whether it is linked to dierent physiological conditions between individuals at the time the samples were collected. Transfection of ZAC splice variants and of various deletion mutants indicated that translation of the new variant is primarily initiated at the ®rst inframe ATG in this variant, giving rise to a protein with 5 ZFs only which we subsequently named ZACD2 (Figure 2b ). This protein was found to be nuclear (Figure 2c ) indicating that amino acids 1 ± 52 do not contribute to the nuclear localization of ZAC. The existence of a splice variant devoid of the exon encoding the 2 N-terminal ZFs has been reported for PLAG1 (Kas et al., 1997; Queimado et al., 1999) , a member of the ZAC family of zinc ®nger proteins whose 3' gene structure is similar to that of ZAC. In contrast to ZAC, PLAG1 splice variant is devoid of the putative nuclear localization signal (Kas et al., 1997) . The characterization of PLAG1 splice variants and of their functional properties has not been reported so far.
The role of C2H2-type ZFs in DNA binding has been recognized since the discovery of this conserved motif in TFIIIA (Hanas et al., 1983; Miller et al., 1985) and alternative splicing of ZFs or within ZF domains was previously described for other ZFPs and resulted in modulation of the DNA binding properties of the corresponding variants in some instances (Bickmore et al., 1992; Cabanillas and Darling, 1996; Gogos et al., 1992; Hsu et al., 1992; Read and Manley, 1992) . We therefore tested whether alternative splicing of ZAC modulates its DNA binding properties. ZF1 and 2 are not involved in direct binding to the G 4 C 4 ZAC consensus binding site since ZACD2 still bound eciently this DNA motif (Figure 3a) . Indeed, deletion of ZF1-2 rather enhanced binding to the G 4 C 4 consensus (Figure 4b ) suggesting that the two Nterminal ZF negatively modulate DNA binding through ZF3-7. It was previously noted that many ZFPs contain more ZFs than actually necessary for sequence-speci®c DNA binding and additional roles have been demonstrated for ZF motifs ranging from intra-molecular modulation of DNA binding by other ZFs (Trainor et al., 2000) , protein-protein interactions (Mackay and Crossley, 1998) to zinc sensor (Chen et al., 1998 (Chen et al., , 1999 . Indeed, it was experimentally determined that two to three ZF domains are sucient for sequence speci®c DNA binding, with each ZF contacting three nucleotides (Klug and Schwabe, 1995) . ZAC comprises seven ZF motifs which suggests that four to ®ve ZF motifs are potentially available for functions other than DNA binding. As suggested for other ZFPs (Mackay and Crossley, 1998) , our results indicate that ZAC contains ZFs which are involved in DNA binding (some of ZF3-7) and ZFs involved in intra-and/or inter-molecular protein ± protein interactions (ZF1-2). Additionally, DNA binding through ZF1-2 to sequences unrelated to G 4 C 4 is not excluded and the determination of target genes of ZAC splice variants in vivo will be of importance in this context.
Both variants behaved similarly in colony formation assays ( Figure 5 ), suggesting that deletion of ZF1-2 did not signi®cantly alter the overall antiproliferative activity of ZAC gene products. In this test, the antiproliferative activity of a gene potentially results from at least two mechanisms; impaired survival through induction of apoptosis and decreased proliferation by induction of cell cycle arrest. We previously showed that the activity of ZAC in colony formation assays resulted from concomitant induction of both mechanisms (Spengler et al., 1997; Varrault et al., 1998) and ZACD2 was found to behave qualitatively similarly (Table 1 and Figure 6 ). However, we showed that whereas ZACD2 was more ecient than ZAC at control of cell cycle progression (Table 1) , it was the reverse for apoptosis induction (Figure 6 ) indicating that ZF1-2 critically modulate the molecular pathways controlled by ZAC. The discovery of a functional specialization of ZAC splice variants is critical to understand the precise mechanism of action of ZAC, though the physiological signi®cance of co-expression of ZAC splice variants in vivo remains to be determined. In that respect, several items, including target genes, partners and regulation of ZAC vs ZACD2 expression, will have to be addressed in further studies. The parallel enhancement of DNA binding and cell cycle arrest by ZACD2 suggests that promoters of ZAC/ZACD2 target genes involved in cell cycle arrest most likely contain ZAC-responsive elements similar to the in vitro-selected G 4 C 4 sequence. On the other hand, ZAC triggered apoptosis more eciently than ZACD2 which suggests that apoptosis was induced through regulation of an additional set of genes whose regulatory sequences do not comprise G 4 C 4 -like sequences or through protein ± protein interactions involving ZF1-2. Finally, one may postulate that ®ne tuning of ZAC vs ZACD2 ratio represents a modulatory mechanism to control the balance between cell cycle arrest and apoptosis, a fundamental event during development, dierentiation and tumorigenesis.
Materials and methods
Cell culture and transfection
Breast cancer cell lines (CAL-51, MDA-MB-157, MCF-7) and the kidney epithelial cell line LLC-PK1 were grown in DMEM supplemented with 10% FBS. LLC-PK1 cells were electroporated as previously described (Spengler et al., 1997) .
Plasmid construction
Details on the construction of the dierent plasmids used in this study are available upon request. Brie¯y, to construct pRK7-ZAC, ZAC cDNA was ampli®ed with primers ghZ-17 (5'-TGGCACAGCATTTGGTCAGC-3') and T3L (5'-AT-TAACCCTCACTAAAAGATGCC-3') on pBS-ZAC plasmid (Varrault et al., 1998) . PCR products were digested with EcoRI and subcloned into pRK7 EcoRI/SmaI. ZACD2 cDNA was subcloned into pRK7 vector using the same PCR strategy with C12-12 primer (5'-CCTCGCAGCA-GATGTTCCCT-3') and T3L primer on pBS-ZACD2. ZACM4 cDNA was constructed by digestion of pBS-ZAC with EcoRI/XmnI and subcloning of the restriction fragment into pRK7 EcoRI/SmaI. ZACM5 cDNA was ampli®ed on pBS-ZAC with primers ZM5 (5'-TAGGATCCTGAG-GAGTGTGGGAAGAAG-3') and T3L, digested with EcoRI/BamHI and subcloned into pRK7 EcoRI/BamHI. To create pRK7-ZACM6, pRK7-ZAC was digested with PpuMI and religated. All clones were sequence veri®ed by sequencing both strands of the PCR ampli®ed cDNA region.
RT ± PCR analysis
Total RNAs were prepared from mammoplasty reduction, cell lines and placenta as described (Chomczynski and Sacchi, 1987) . Pituitary gland poly A + RNA, human fetal liver and human kidney total RNA were from Clontech (Palo Alto, CA, USA) and human ovary total RNA was from Research Genetics, Inc. (Huntsville, AL, USA). One mg of total RNA or 0.5 mg of poly A + RNA were reverse transcribed using M-MLV reverse transcriptase as previously described (Bilanges et al., 1999) . Semi-quantitative PCR was performed using primers C12-12 and ghZ-10 (5'-GCGGAGGAGAGC-CAGGGGATACC-3').
Western blotting and immunohistochemistry
Western blots were performed on total lysate (10 mg) prepared from transfected cell or on nuclear extracts prepared as described (Scharnhorst et al., 1997) . ZAC antiserum was collected from rabbit immunized with a GST-ZAC(226 ± 463) fusion protein. Western blots were performed with anti-ZAC antiserum (1/2000) and peroxydase-conjugated anti-rabbit Ig (Amersham). For immunocytochemistry, transfected cells grown on coverslips were ®xed-permeabilized and incubated with the anti-ZAC antiserum and stained with a FITC-conjugated anti-rabbit Ig (Sigma).
Electrophoretic mobility shift assay (EMSA) and transactivation of luciferase gene reporter assay Three pmol of a 25 bp synthetic oligodeoxynucleotide containing the ZAC DNA binding motif (G 4 C 4 : 5'-GTACTAACAGGGGCCCCATTTAATC-3') (Varrault et al., 1998) was labeled with [g-32 P]-ATP (10 mCi) using T4 polynucleotide kinase for 15 min, at 378C. After Biospin-6 puri®cation, 5 mg of nuclear extracts and 50 000 c.p.m. were incubated in binding buer (HEPES 20 mM pH 7.9, MgCl2 50 mM, glycerol 10%, KCl 70 mM, ZnSO4 10 mM, poly(dIdC) 0.5 mg, salmon sperm DNA 0.3 mg, DTT 0.5 mM) for 25 min at room temperature. DNA-protein complexes were separated on a 7% polyacrylamide gel and visualized by autoradiography. Band intensities were quantitated using BioRad GS-525 Molecular Imager System. For transactivation experiments, ®ve copies of the G 4 C 4 consensus sequence were subcloned in pGL2 vector containing the E1B TATA box upstream of the luciferase reporter gene. Two mg of pGL2-(G 4 C 4 )5-E1BLuc plasmid and 1 mg of ZAC cDNA constructs were cotransfected in LLC-PK1 cells. Cells were harvested 24 h later and luciferase activity was measured using a ML3000 luminometer (Dynatech).
Colony formation assay
LLC-PK1 cells were transfected with 4 mg pRK5-CAT or cotransfected with 200 ng pRK5-PUR and 4 mg of either pRK5-CAT, pRK5-ZACas, pRK7-ZAC or pRK7-ZACD2. Expression of each construct was monitored after 24 h by Western blotting. Selection with 2 mg/ml puromycin was started 48 h following transfection and colonies were scored at 10 d.
Quantification of apoptotic cells
LLC-PK1 cells were transiently cotransfected with 100 ng of plasmid encoding rat CD2DC (pRK5-CD2DC) and 1 mg of pRK-b-galactosidase, 0.5 mg of pRK-HA-p53 or 2 mg of pRK7-ZAC or pRK7-ZACD2. The percentage of apoptotic cells was determined as previously described (Lassus and Hibner, 1998) but for ®xation which was omitted.
Cell cycle analysis
Cells were transfected as above. Forty-eight hours later, cells were prepared and stained with 0.5 mg FITC-conjugated anti-CD2 antibody and 50 mg/ml propidium iodide as previously described (Varrault et al., 1998) . Propidium iodide and FITC uorescence intensity was determined using a FACScan¯ow cytometer (Becton-Dickinson) and the cell cycle distribution of the 10% most CD2-positive cells was analysed using Mod®t software (Verity Software House).
Accession number
The accession number for the novel sequence reported in this manuscript (ZACD2) is AJ303119. 
